No Data
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Seems To Use Debt Quite Sensibly
Jolly Pharmaceutical to Take Controlling Stake in Lingyi Biotech in Cooperation Deal; Shares Up 3%
Zhejiang Jolly Pharmaceutical (300181.SZ): Signed a global strategy cooperation framework agreement with Lingyi Biotechnology.
On November 20th, Jolly Pharmaceutical (300181.SZ) announced that the company has signed a "Strategic Cooperation Framework Agreement" with Lingyi (Hangzhou) Biotechnology Co., Ltd. According to the agreement, the two parties will establish a long-term and in-depth strategic cooperation relationship. The main areas of cooperation include equity cooperation, research and development cooperation, sales cooperation, and product cooperation. In terms of equity cooperation, Jolly Pharmaceutical will increase its capital to become the second largest shareholder of Lingyi Biotech (Series A round). In terms of research and development cooperation, the two parties will jointly develop innovative drugs for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Jumps 6.5% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns
Zuoli Pharmaceuticals: third quarter report 2024
Zhejiang Jolly Pharmaceutical (300181.SZ) plans to launch an employee stock ownership plan in 2024.
Zhejiang Jolly Pharmaceutical (300181.SZ) released the 2024 employee stock ownership plan (draft), the employee stock ownership plan is expected to raise...
Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
No Data
